A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function

Inclusion Criteria: * Body weight must be ≥ 50 kg and \< 130 kg with a BMI ≤ 38.0 (kg/m2). * Must use acceptable form of birth control during the course of the study and for 3 months following the single dose of study drug. * Female subjects of childbearing potential must have a negative pregnancy test at screening and check-in. * Negative test for HIV; hepatitis A, B, and C. * Must have adequate vital sign reads at screening and check-in. * Must be able to comply with dietary and fluid restrictions required for the study. Exclusion Criteria: * History of medical or surgical conditions that would interfere with GI absorption, distribution, metabolism, or excretion of the study drug. * Recent clinical evidence of pancreatic injury. * Recent use of drugs known to significantly inhibit or induce P450 CYP3A4 enzymes. * Previous diagnosis of malignancy. * Unwilling to forgo use of any over-the-counter or non-prescription preparations.